Imagine sifting through medical and genetic histories to understand why some patients respond to treatments while others don’t. This is the reality for companies like Merck & Co. A recent pact with Culmination Bio is giving Merck access to more than 40 years of data, including millions of biospecimens to fuel this aim. “We want…